Browsing by author "Minchom, Anna"
Now showing items 21-28 of 28
-
Real-world outcomes in thoracic cancer patients with severe Acute respiratory syndrome Coronavirus 2 (COVID-19): Single UK institution experience.
Cui, W; Yousaf, N; Bhosle, J; Minchom, A; Nicholson, AG; et al. (Elsevier BV, 2020-01-01)BACKGROUND: UK COVID-19 mortality rates are amongst the highest globally. Controversy exists on the vulnerability of thoracic cancer patients. We describe the characteristics and sequelae of patients with thoracic cancer ... -
Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation - a Single Unit Experience.
Biondo, A; Pal, A; Riisnaes, R; Shinde, R; Tiu, C; et al. (Elsevier BV, 2021-01-11)Early-phase cancer clinical trials are becoming increasingly accessible for patients with advanced cancer who have exhausted standard treatment options and later phase trial options. Many of these trials mandate research ... -
Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy.
Castagnoli, F; Doran, S; Lunn, J; Minchom, A; O'Brien, M; et al. (Public Library of Science (PLoS), 2022-01-01)INTRODUCTION: The spleen is a lymphoid organ and we hypothesize that clinical benefit to immunotherapy may present with an increase in splenic volume during treatment. The purpose of this study was to investigate whether ... -
Statistical methods and data visualisation of patient-reported outcomes in early phase dose-finding oncology trials: a methodological review.
Alger, E; Minchom, A; Lee Aiyegbusi, O; Schipper, M; Yap, C (ELSEVIER, 2023-10-01)BACKGROUND: Traditionally, within dose-finding clinical trials, treatment toxicity and tolerability are assessed by clinicians. Research has shown that clinician reporting may have inadequate inter-rater reliability, poor ... -
Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT).
Pal, A; Stapleton, S; Yap, C; Lai-Kwon, J; Daly, R; et al. (BMJ PUBLISHING GROUP, 2021-09-06)INTRODUCTION: Early phase cancer clinical trials have become increasingly complicated in terms of patient selection and trial procedures-this is reflected in the increasing length of participant information sheets (PIS). ... -
Trends in patient-reported outcome use in early phase dose-finding oncology trials - an analysis of ClinicalTrials.gov.
Lai-Kwon, J; Yin, Z; Minchom, A; Yap, C (WILEY, 2021-11-01)BACKGROUND: Patient-reported adverse events (AEs) may be a useful adjunct to clinician-assessed AEs for assessing tolerability in early phase, dose-finding oncology trials (DFOTs). We reviewed DFOTs on ClinicalTrials.gov ... -
Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients.
Cui, W; Milner-Watts, C; O'Sullivan, H; Lyons, H; Minchom, A; et al. (ELSEVIER SCI LTD, 2022-08-01)BACKGROUND: Genomic sequencing is necessary for first-line advanced non-small cell lung cancer (aNSCLC) treatment decision-making. Tissue next generation sequencing (NGS) is standard but tissue quantity, quality, and ... -
Using Patient-Reported Outcomes in Dose-Finding Oncology Trials: Surveys of Key Stakeholders and the National Cancer Research Institute Consumer Forum.
Lai-Kwon, J; Vanderbeek, AM; Minchom, A; Lee Aiyegbusi, O; Ogunleye, D; et al. (OXFORD UNIV PRESS, 2022-09-02)BACKGROUND: Patient-reported adverse events may be a useful adjunct for assessing a drug's tolerability in dose-finding oncology trials (DFOT). We conducted surveys of international stakeholders and the National Cancer ...